Proactive Research analyst Emma Ulker discusses MaxCyte’s (LON:MXCT) new clinical and commercial licence agreement with Caribou Biosciences.
She says the agreement which allows the use of its proprietary Flow Electroporation technology for Caribou’s CRISPR gene-edited allogeneic T-cell therapy programmes is the latest in a series of late-stage clinical and commercial collaborations in cell and gene therapy.